• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    DaVita Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    6/9/25 4:31:13 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care
    Get the next $DVA alert in real time by email
    dva-20250605
    0000927066false00009270662025-06-052025-06-05


     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     Form 8-K 

     CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the
    Securities Exchange Act of 1934
     
    Date of Report (date of earliest event reported): June 5, 2025
     

     
    DAVITA INC.
    (Exact name of registrant as specified in its charter)
     

     
    DE1-1410651-0354549
    (State or other jurisdiction
    of incorporation)
    (Commission File Number)(IRS Employer
    Identification No.)
     
    2000 16th Street
    Denver,CO80202
    (Address of principal executive offices including Zip Code)
     
    (720) 631-2100
    (Registrant’s telephone number, including area code)
     
    Not applicable
    (Former name or former address, if changed since last report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
    ☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 240.425)
     
    ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each class: Trading symbol(s):Name of each exchange on which registered:
    Common Stock, $0.001 par value DVANew York Stock Exchange




    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    ☐    Emerging growth company
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐





    Item 5.07.    Submission of Matters to a Vote of Security Holders.

    On June 5, 2025, DaVita Inc. (the “Company”) held its virtual 2025 Annual Meeting of Stockholders (the “Annual Meeting”). Represented virtually or by proxy at the Annual Meeting were 69,548,287 shares of the Company's common stock, or approximately 90% of its outstanding shares of common stock as of April 9, 2025, the record date of the Annual Meeting. The proposals presented at the Annual Meeting are described in detail in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 24, 2025. The vote results detailed below represent final results as certified by the Inspector of Elections.

    Proposal 1. Election of Directors.
    The Company’s stockholders elected the nine director nominees named below to the Company’s Board of Directors for a term expiring at the 2026 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified. The voting results are as follows:
    Name of Nominee
    For
    Against
    Abstain
    Broker non-votes
    Pamela M. Arway61,548,8221,542,30823,6216,433,536
    Barbara J. Desoer62,068,5831,022,59223,5766,433,536
    Jason M. Hollar62,380,680708,42925,6426,433,536
    Gregory J. Moore, MD, PhD63,031,22458,18425,3436,433,536
    Dennis W. Pullin63,035,55323,75055,4486,433,536
    Javier J. Rodriguez63,066,38121,98426,3866,433,536
    Adam H. Schechter62,872,915217,12724,7096,433,536
    Wendy L. Schoppert62,867,043223,10424,6046,433,536
    Phyllis R. Yale62,900,167191,03123,5536,433,536
    Proposal 2. Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm.
    The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The voting results are as follows:
    For Against Abstain
    66,500,6823,022,68324,922
    Proposal 3. Advisory vote to approve named executive officer compensation.
    The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers. The voting results are as follows:
    For Against Abstain Broker non-votes
    59,322,4253,527,754264,5726,433,536









    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
    DAVITA INC.
    Date: June 9, 2025By:/s/ Samantha Caldwell
    Samantha Caldwell
    Corporate Secretary




    Get the next $DVA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DVA

    DatePrice TargetRatingAnalyst
    3/6/2024$133.00Equal Weight
    Barclays
    8/7/2023$100.00 → $142.00Neutral → Buy
    UBS
    11/1/2022$97.00 → $72.00Buy → Hold
    Deutsche Bank
    10/31/2022$117.00 → $74.00Buy → Neutral
    UBS
    8/19/2022$106.00 → $117.00Buy
    UBS
    6/21/2022$110.00 → $90.00Underperform
    BofA Securities
    1/5/2022$114.00 → $125.00Hold
    Truist Securities
    10/29/2021$113.00 → $111.00Sector Perform
    RBC Capital
    More analyst ratings

    $DVA
    SEC Filings

    See more
    • SEC Form 11-K filed by DaVita Inc.

      11-K - DAVITA INC. (0000927066) (Filer)

      6/13/25 4:26:44 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - DAVITA INC. (0000927066) (Filer)

      6/9/25 4:31:13 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - DAVITA INC. (0000927066) (Filer)

      5/23/25 4:28:44 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care

    $DVA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • DaVita Statement on Government's Kidney Care Choices (KCC) Model Updates

      DENVER, May 30, 2025 /PRNewswire/ -- DaVita, a comprehensive kidney care company, issued the following statement in response to updates this week from the Center for Medicare and Medicaid Innovation (CMMI) related to its Kidney Care Choices (KCC) Model. It can be attributed to Misha Palecek, chief transformation officer for DaVita. "As a dedicated participant in the government's value-based care initiative and a pioneer in this field for the last twenty years, we applaud CMMI's decision to extend the Kidney Care Choices (KCC) Model for an additional year. We believe the investments made by CMMI and participants alike will result in long-term savings in the upcoming years. The program's emph

      5/30/25 2:35:00 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita Releases Annual Community Care Report, Highlights Achievements in Corporate Citizenship

      Captures key initiatives achieved in 2024, driving 2025 ESG goals DENVER, May 20, 2025 /PRNewswire/ -- Today, DaVita (NYSE:DVA) published its Community Care report, underpinning its long-standing commitment to corporate citizenship and highlighting strides made towards ambitious Environmental, Social and Governance (ESG) goals set to be achieved this year. Milestones and achievements reflect calendar year 2024. In 2021, DaVita announced broadened ESG goals and has since reported progress against its five strategic focus areas: Patient Care, Teammate Engagement, Environmental Stewardship, Healthy Communities and Leading with Integrity and Accountability. "This year, we're celebrating 25 years

      5/20/25 9:05:00 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita Inc. 1st Quarter 2025 Results

      DENVER, May 12, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended March 31, 2025. "Our strong first quarter performance demonstrates the stability and consistency of our operating model" said Javier Rodriguez, CEO of DaVita Inc. "We maintain a steadfast commitment to being the provider, employer and partner of choice and returning value to our shareholders." Financial and operating highlights for the quarter ended March 31, 2025: Consolidated revenues were $3.224 billion.Operating income was $439 million.Diluted earnings per share was $2.00.Operating cash flow was $180 million and free cash flow was $(45) million.Repurchased 3.7 milli

      5/12/25 4:05:00 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care

    $DVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Barclays initiated coverage on DaVita with a new price target

      Barclays initiated coverage of DaVita with a rating of Equal Weight and set a new price target of $133.00

      3/6/24 8:09:27 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita upgraded by UBS with a new price target

      UBS upgraded DaVita from Neutral to Buy and set a new price target of $142.00 from $100.00 previously

      8/7/23 7:20:56 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita downgraded by Deutsche Bank with a new price target

      Deutsche Bank downgraded DaVita from Buy to Hold and set a new price target of $72.00 from $97.00 previously

      11/1/22 9:18:39 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care

    $DVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Moore Gregory J. was granted 348 shares, increasing direct ownership by 6% to 6,451 units (SEC Form 4)

      4 - DAVITA INC. (0000927066) (Issuer)

      5/16/25 9:15:16 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • Director Berg Charles was granted 348 shares, increasing direct ownership by 2% to 19,982 units (SEC Form 4)

      4 - DAVITA INC. (0000927066) (Issuer)

      5/16/25 9:15:04 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • Director Yale Phyllis R was granted 348 shares, increasing direct ownership by 3% to 13,201 units (SEC Form 4)

      4 - DAVITA INC. (0000927066) (Issuer)

      5/16/25 9:14:55 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care

    $DVA
    Leadership Updates

    Live Leadership Updates

    See more
    • DaVita Appoints Jessica Hergenreter as Chief People Officer

      DENVER, Oct. 17, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced Jessica (Jess) Hergenreter as its new chief people officer (CPO). In this position, Hergenreter will oversee DaVita's People Services team, leading initiatives to engage and uplift DaVita's more than 70,000 teammates (employees) worldwide. Earlier this year, DaVita was named as a Top Workplace by USA Today and one of America's Most Loved Companies by Newsweek. "Our incredible teammates are the difference makers for the care we provide to patients," said Javier Rodriguez, C

      10/17/24 1:00:00 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita Appoints David Maughan New Chief Operating Officer, Mike Staffieri Steps into Emeritus Role

      DENVER, Sept. 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that David Maughan will assume the role of chief operating officer. This appointment builds on Maughan's 18-year tenure at DaVita in a range of leadership roles. After a celebrated 11-year tenure as chief operating officer, Mike Staffieri will step into the role of chief operating officer emeritus. Both appointments are effective September 15, 2024. "It's an exciting time for DaVita! Dave's extensive experience in operations leadership coupled with his deep knowledge of DaVita's business positions him well to build upon our incredible foundation of operational excellence and lead our on

      9/13/24 8:00:00 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita Appoints New Chief Information Officer

      Madhu Narasimhan named to leadership role to accelerate technology-based innovations at DaVita  DENVER, May 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that Madhu Narasimhan will assume the role of chief information officer (CIO), effective June 3, 2024. In this leadership position, Narasimhan will be responsible for accelerating the implementation of DaVita's industry-leading health technology platforms. She will oversee DaVita's technology innovation strategy, including enterprise priorities like Center Without Walls™ (CWOW®),

      5/13/24 9:00:00 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care

    $DVA
    Financials

    Live finance-specific insights

    See more
    • DaVita Inc. 1st Quarter 2025 Results

      DENVER, May 12, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended March 31, 2025. "Our strong first quarter performance demonstrates the stability and consistency of our operating model" said Javier Rodriguez, CEO of DaVita Inc. "We maintain a steadfast commitment to being the provider, employer and partner of choice and returning value to our shareholders." Financial and operating highlights for the quarter ended March 31, 2025: Consolidated revenues were $3.224 billion.Operating income was $439 million.Diluted earnings per share was $2.00.Operating cash flow was $180 million and free cash flow was $(45) million.Repurchased 3.7 milli

      5/12/25 4:05:00 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita Inc. Schedules 1st Quarter 2025 Investor Conference Call

      DENVER, April 30, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss first quarter results on Monday, May 12, 2025, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows:  Monday, May 12, 2025Starting at 5:00 p.m. EDTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042 When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen to the

      4/30/25 11:00:00 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita Inc. 4th Quarter 2024 Results

      DENVER, Feb. 13, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended December 31, 2024. "Despite a year with unique hurdles, we finished strong in 2024, producing full year adjusted operating income and adjusted EPS in the top half of our guidance range," said Javier Rodriquez, CEO of DaVita Inc. "As we embark on 2025, when we will be celebrating the 25th anniversary of DaVita, we look forward to continuing our efforts to improve clinical outcomes, enhance quality of life for our patients and teammates, and be a force for positive change in the healthcare system." Financial and operating highlights for the quarter and year ended Decembe

      2/13/25 4:05:00 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care

    $DVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by DaVita Inc. (Amendment)

      SC 13G/A - DAVITA INC. (0000927066) (Subject)

      2/13/24 5:02:42 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13G/A filed by DaVita Inc. (Amendment)

      SC 13G/A - DAVITA INC. (0000927066) (Subject)

      2/9/22 3:43:35 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13D/A filed by DaVita Inc. (Amendment)

      SC 13D/A - DAVITA INC. (0000927066) (Subject)

      8/4/21 4:02:59 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care